Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

186 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disease. A Dutch study recently proved that thoracic radiotherapy(TRT), using 30 Gy in 10 fractions of 3 Gy, could improve 2-year overall survival(OS) of this patient group compared with non-TRT group. But intrathoracic progression was still high, either with or without progression elsewhere, occurring in 43.7% in the TRT group. The ideal TRT regimen for ES-SCLC is undefined. Maybe higher dose can provide better local control(LC) and overall survival. In this study, the investigators propose to give an increased dose of TRT to determine whether higher dose will improve 2-year OS, LC and progression-free survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer

NCT05557552

Non-small Cell Lung Cancer Stage III

RECRUITING NA

First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy

NCT06586697

Extensive-stage Small-cell Lung Cancer

RECRUITING PHASE2

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

NCT06732258

Extensive-stage Small-cell Lung Cancer

NOT_YET_RECRUITING PHASE1

Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC

NCT02990780

SCLC

UNKNOWN PHASE3

Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy

NCT05552846

Small-cell Lung Cancer

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, prospective, randomised phase III study. For patients with ES-SCLC who respond to chemotherapy after four to six cycles of standard chemotherapy (platinum etoposide), 45Gy/15F of thoracic radiotherapy will be used in experimental arm, while 30Gy/10F of thoracic radiotherapy will be used in the control arm. Both survival and toxicity of the two arms will be observed and compared.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Small Cell Lung Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

high-dose TRT

high-dose thoracic radiotherapy X-ray RT

Group Type EXPERIMENTAL

high-dose TRT

Intervention Type RADIATION

every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f

standard-dose TRT

standard-dose thoracic radiotherapy XRT

Group Type ACTIVE_COMPARATOR

standard-dose TRT

Intervention Type RADIATION

every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

high-dose TRT

every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f

Intervention Type RADIATION

standard-dose TRT

every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 - 70 years old, ECOG 0-2.
* Patients with histologically or cytologically proved small cell lung cancer.
* Extensive stage small-cell lung cancer (ES-SCLC), was characterized by tumors beyond the hemithorax, hilar, mediastinal, and supraclavicular nodes. According to 2007 AJCC cancer staging 7th edition, stage I-IIIB with lung metastases and stage IV should be defined as LD.
* Has 1-4 extracranial metastatic lesions.
* No brain or central nervous system (CNS) metastases.
* No prior history of anti-tumor treatment.
* Response after 4 to 6 cycles of EP-based chemotherapy within the past 4 weeks.
* No severe internal diseases and no organ dysfunction.
* Written informed consent provided.

Exclusion Criteria

* Malignant tumors of other sites. Non melanoma skin cancer and Cervical carcinoma in situ were not included if curable.
* Active heart disease or acute myocardial infarction happen in six months.
* Psychiatric history.
* Pregnant woman or woman need to breast feed or woman with positive chorionic gonadotrophin (HCG).
* Uncontrolled diabetes or hypertension.
* Interstitial pneumonia or Active pulmonary fibrosis.
* Acute bacterial or fungal infection.
* Oral or intravenous use of steroids.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No